Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. - Wikidata - awgldk - TriplyDB

Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.

Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.

http://www.wikidata.org/entity/Q38032568

about

The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases Oral Apremilast for the Treatment of Plaque Psoriasis Selective Phosphodiesterase 4B Inhibitors: A Review Thalidomide-a notorious sedative to a wonder anticancer drug.Cyclic AMP concentrations in dendritic cells induce and regulate Th2 immunity and allergic asthma.Small Molecules in the Treatment of Psoriasis.A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE).Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.The effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study.Targeting cAMP in chronic lymphocytic leukemia: a pathway-dependent approach for the treatment of leukemia and lymphoma.Advances in treating psoriasis.Novel investigational therapies for atopic dermatitis.New treatments for inflammatory rheumatic disease.Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.Apremilast for the treatment of psoriasis.Apremilast for the treatment of psoriatic arthritis.A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.Nonribosomal peptides and polyketides of Burkholderia: new compounds potentially implicated in biocontrol and pharmaceuticals.Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1 [Guidelines for vaccination of immunocompromised individuals].Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum Apremilast in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Pilot Study.Next-generation antipsoriatic drugs: small molecules join.Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice: Involvement of p38 and JNK Signaling Pathways.East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease.Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats.

P2860

Q26750377-BCE345C0-3E10-4D0E-828A-DEBE0E7E2980 Q28075724-4A810D73-B4B7-4E17-9EF9-52BFC88079B2 Q28081071-2BA6478C-5636-431C-B488-F5C9FEFCCF15 Q33956871-39B4CDB7-0FEA-430F-BEA1-92C1678016A2 Q35062625-CE4CA595-9B59-4767-9EC3-3AAFEA5222F3 Q35740706-C5921670-917B-4FA9-AE16-0B09A5DFAC27 Q35937121-1C0BF2BD-6452-40E9-9CBF-DD2362DE8764 Q36061710-E7609887-BB44-42C1-9487-068F64C863EE Q37104915-97D8775C-8C91-4A30-90DA-CA912FFBB2B4 Q38104404-37DB35B2-C304-4F23-9E46-47E7C11C5879 Q38193099-D923E9C5-2488-4718-A301-D1693E5A07F1 Q38247119-3BFEBD46-F920-47A4-B82C-4929E81EE987 Q38266252-CB9007CA-47E9-4E81-9CD4-24E8376EFC31 Q38416536-F63A447B-99A2-43C9-809F-5976A94026C8 Q38543069-95331176-E668-4C25-968B-80609EFF6DF8 Q38561061-CD188FBA-077C-4D06-B603-3873963A8553 Q38616811-BE5C7014-B49E-4A74-BB3D-BFFD646D95A7 Q38675867-0E2C1B06-670F-47C8-A5C1-8E434EC1854B Q38762222-000B96E6-2478-414B-B2B4-1FA2E6B3DC6C Q38766379-6F9203BA-F973-49B4-9741-F5AE7C7F47E2 Q38885459-9D68AAE5-1DEA-48AD-BC6F-99D849B0A162 Q39375417-9E72CACD-4BAF-47D9-9279-7FF498C0FF0E Q40204659-DB75962B-69C7-417D-8365-9F8DDD183A5C Q40600058-159C9B84-4EE7-4077-9059-F9374629FDCE Q41540546-B2ABD026-E132-49B5-B577-0E33E7383FE8 Q42291222-5CA25156-BE0D-4D0F-9648-9E9CC0FAA7D1 Q48225472-107493D5-4599-487C-A603-76DBFC8CF7F3 Q48273986-1DA4D914-2601-4258-BC08-BAE61C8F9C36 Q50117437-44D9C68B-C360-4451-807C-6FF94D346688 Q51733163-86237803-A5DE-4FF0-9DB6-BCFD2B48E399 Q51772071-D7AAD684-9199-493C-BBB1-36FFB5E88850

P2860

Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.

http://www.wikidata.org/entity/Q38032568

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Apremilast: a novel PDE4 inhib ...... une and inflammatory diseases.

@en

type

label

Apremilast: a novel PDE4 inhib ...... une and inflammatory diseases.

@en

prefLabel

Apremilast: a novel PDE4 inhib ...... une and inflammatory diseases.

@en

P1433

Q38032568-A440A537-26EA-48C0-BFD3-CD01C0DBD2E0

P1476

Q38032568-DEC36C85-BDBB-4B14-98ED-15CA2CFF2A2F

P2093

Q38032568-272CFDE8-0E92-4312-9EB3-8C24B49A65B3

Q38032568-6D4BE0DB-8377-4954-A00E-E726B4307775

Q38032568-C7947325-16AB-4120-ADDC-F67200C75374

P2860

Q38032568-180667C6-CAB5-4576-8821-C9D85A767CA7

Q38032568-25DA3833-D3DA-4E09-85E8-648E57287E64

Q38032568-33ECF8CA-8F83-40D8-81EC-0C192D8E63BA

Q38032568-37B70F51-B988-410E-AA2D-82A7C256464D

Q38032568-3E4BE36E-B42C-4912-B5E9-A55A3B44703E

Q38032568-3F9039D5-51C1-4010-B870-4D394F3916CE

Q38032568-455A67CD-32C7-4546-9458-F496FF8F358B

Q38032568-57E8F8B5-45C6-4949-80F8-6C36C5D5436C

Q38032568-6111EE62-E617-44FD-ACD9-AE74C3D60342

Q38032568-64F9D0E0-64A0-48CC-A0F8-34295974D09D

P304

Q38032568-86286FC8-A31D-4175-AC49-89BC1D212D07

P31

Q38032568-7EF2D135-FEA1-414C-AF62-A03915331B78

P356

Q38032568-FEDC09F7-16DB-4105-B0BE-954CF4F8AEB1

P433

Q38032568-C6D89F3A-9907-4756-A7C0-B7A8703DB61B

P478

Q38032568-C6978FA6-5580-4B90-A701-7A462EA6134E

P50

Q38032568-F97C1B95-4E1E-40C9-9A45-EB0419355786

P577

Q38032568-67D8EBF3-0D18-4708-B249-93252D6B21FB

P698

Q38032568-8C68E1B0-B522-4704-A876-FE768D39BEC6

P921

Q38032568-46838835-306C-4053-AF48-CF09EEFD0D57

P932

Q38032568-B6E25763-66D3-43BF-85E2-8DF6067F2755

P356

1759720X10381432

P1433

Therapeutic advances in musculoskeletal disease

P1476

Apremilast: a novel PDE4 inhib ...... une and inflammatory diseases.

@en

P2093

Peter Schafer

http://www.w3.org/2001/XMLSchema#string

Randall M Stevens

http://www.w3.org/2001/XMLSchema#string

Victor S Sloan

http://www.w3.org/2001/XMLSchema#string

P2860

Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis

The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform

Keynote review: phosphodiesterase-4 as a therapeutic target

Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2

Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.

Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.

PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization

Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells.

P304

271-278

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1759720X10381432

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22870453

http://www.w3.org/2001/XMLSchema#string

P921

P932

3383510

http://www.w3.org/2001/XMLSchema#string